APA (7th ed.) Citation
Haque, A. A. (2026). AN IN-SILICO APPROACH TO REPURPOSE FDA-APPROVED PROPRANOLOL AGAINST PD-L1 PROTEIN TARGET IN CANCER TREATMENT. BME DEPT. MIST.
Chicago Style (17th ed.) Citation
Haque, AKM Arefen. AN IN-SILICO APPROACH TO REPURPOSE FDA-APPROVED PROPRANOLOL AGAINST PD-L1 PROTEIN TARGET IN CANCER TREATMENT. Dhaka: BME DEPT. MIST, 2026.
MLA (9th ed.) Citation
Haque, AKM Arefen. AN IN-SILICO APPROACH TO REPURPOSE FDA-APPROVED PROPRANOLOL AGAINST PD-L1 PROTEIN TARGET IN CANCER TREATMENT. BME DEPT. MIST, 2026.
Warning: These citations may not always be 100% accurate.